Bristol-Myers v. Biocraft
Executive Summary
Bristol-Myers received a preliminary injunction prohibiting Biocraft from marketing its generic cefadroxil antibiotic on Feb. 28, Bristol announced in a same-day release. Newark Federal Court Judge Dickenson Debevoise determined that the generic product would infringe on Bristol-Myers' crystalline cefadroxil monohydrate patent, due to expire in 2002. Bristol-Myers is seeking a full trial in order to obtain a permanent injunction. Biocraft has 90 days to appeal the ruling to the U.S. Court of Appeals.